Who makes Montelukast placebo granüle?

Montelukast placebo granüle is developed by Kecioren Education and Training Hospital.

What development phase is Montelukast placebo granüle in?

Montelukast placebo granüle is FDA-approved (marketed).

What are the side effects of Montelukast placebo granüle?

Common side effects include Headache, Diarrhea, Nausea, Abdominal pain, Dyspepsia.

Last reviewed 2026-05-15 · How we verify

Montelukast placebo granüle

Kecioren Education and Training Hospital · FDA-approved active Small molecule

Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction.

Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce airway inflammation and bronchoconstriction. Used for Asthma (maintenance and acute treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.

At a glance

Generic name	Montelukast placebo granüle
Also known as	Montelukast placebo granule
Sponsor	Kecioren Education and Training Hospital
Drug class	Leukotriene receptor antagonist
Target	CysLT1 receptor
Modality	Small molecule
Therapeutic area	Respiratory / Immunology
Phase	FDA-approved

Mechanism of action

Montelukast selectively antagonizes cysteinyl leukotriene receptors (CysLT1) on airway smooth muscle and inflammatory cells. By blocking these receptors, it prevents the inflammatory cascade triggered by leukotrienes, which are potent mediators released during allergic and asthmatic responses. This reduces airway edema, mucus secretion, and smooth muscle contraction, improving airflow and reducing asthma symptoms.

Approved indications

Asthma (maintenance and acute treatment)
Allergic rhinitis
Exercise-induced bronchoconstriction

Common side effects

Headache
Diarrhea
Nausea
Abdominal pain
Dyspepsia

Key clinical trials

Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Montelukast placebo granüle CI brief — competitive landscape report
Montelukast placebo granüle updates RSS · CI watch RSS
Kecioren Education and Training Hospital portfolio CI